Example: confidence

Search results with tag "Erlotinib"

DRUG NAME: Erlotinib - BC Cancer

DRUG NAME: Erlotinib - BC Cancer

www.bccancer.bc.ca

Erlotinib BC Cancer Agency Cancer Drug Manual© Page 1 of 5 Erlotinib Developed: December 2005 Limited revision: 1 April 2009, 1 June 2010, 1 April 2011, 1 July 2014 DRUG NAME: Erlotinib

  Name, Drug, Drug name, Erlotinib

List of API Intermediates CAS No Intermediate Structure

List of API Intermediates CAS No Intermediate Structure

www.synpurelabs.com

List of API Intermediates Drug Name CAS No Intermediate Structure Dapiprazole 39512-51-1 1-(o-Tolyl) Piperazine HN N Erlotinib 6,7-dihydroxy quinazoline N N HO HO Erlotinib

  Name, Drug, Lists, Structure, Intermediate, Erlotinib, List of api intermediates cas no intermediate structure, List of api intermediates drug name cas no intermediate structure

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

www.ema.europa.eu

Erlotinib is eliminated by hepatic metabolism and biliary excretion. Although erlotinib exposure was similar in patients with moderately impaired hepatic function (Child-Pugh score 7-9) compared with

  Product, Summary, Characteristics, Summary of product characteristics, Erlotinib

Symptom Management Guidelines: ACNEIFORM …

Symptom Management Guidelines: ACNEIFORM

www.bccancer.bc.ca

• Patients ofAsian descent are found to be slightly more susceptible to symptom when taking Gefitinib, Erlotinib or Afatanib.

  Guidelines, Management, Symptom, Symptom management guidelines, Erlotinib, Acneiform

Tarceva - European Medicines Agency

Tarceva - European Medicines Agency

www.ema.europa.eu

changes to an approved test procedure PSUSA/1255/ 201711 Periodic Safety Update EU Single assessment - erlotinib 14/06/2018 n/a PRAC Recommendation - maintenance

  Erlotinib, Tarceva

Similar queries